Deficiency of MSH2 expression is associated with clear cell renal cell carcinoma

Yoo,Koo  Han; Won,Kyu  Yeoun; Lim,Sung‑Jig; Park,Yong‑Koo; Chang,Sung‑Goo

doi:10.3892/ol.2014.2482

Deficiency of MSH2 expression is associated with clear cell renal cell carcinoma

Authors:
- Koo Han Yoo
- Kyu Yeoun Won
- Sung‑Jig Lim
- Yong‑Koo Park
- Sung‑Goo Chang
View Affiliations

Affiliations: Department of Urology, School of Medicine, Kyung Hee University, Seoul 130‑702, Republic of Korea, Department of Pathology, School of Medicine, Kyung Hee University, Seoul 130‑702, Republic of Korea
Published online on: August 26, 2014 https://doi.org/10.3892/ol.2014.2482
Pages: 2135-2139

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA hypermethylation plays a major role in the regulation of gene expression in differentiation, development and diseases. The DNA mismatch repair system, which includes Mut‑S‑Homologon‑2 (MSH2) protein, is essential to maintain the stability of the genome during repeated duplication. This study aimed to investigate tumoral MSH2 immunohistochemical expression in clear cell renal cell carcinoma (RCC), and the associations between tumoral MSH2 immunohistochemical expression and clinicopathological parameters. Previously, we reported a high‑throughput method for analyzing the methylation status of 807 preselected genes; Illumina's GoldenGate Methylation Cancer Panel I microarray. The MSH2 gene was identified to be hypermethylated in cancer tissue compared with normal tissue. From January 2000 to December 2012, 129 clear cell RCC cases (median age, 61 years) were included in the immunohistochemical analysis of the present study. Patients were divided according to MSH2 expression status (MSH2‑negative, n=53; MSH2‑positive, n=76). T stage was significantly higher in the MSH2‑negative group than in the MSH2 positive‑group (P=0.021). There was no significant difference in terms of N stage, M stage and Fuhrman's nuclear grade between the MSH2‑negative and MSH2‑positive group (N stage, P=0.072; M stage, P=0.759; Fuhrman's nuclear grade, P=0118). The MSH2‑negative group showed decreased rates of recurrence‑free survival, progression‑free survival and overall survival, without statistically significant results (P=0.232, P=0.268 and P=0.311, respectively). MSH2 protein expression may be a useful marker for predicting TNM stage and prognosis and, thus, MSH2 may be a prognostic factor in clear cell RCC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.
2	Kim H, Cho NH, Kim DS, et al: Renal cell carcinoma in South Korea: a multicenter study. Hum Pathol. 35:1556–1563. 2004.
3	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009.
4	Figlin R, Sternberg C and Wood CG: Novel agents and approaches for advanced renal cell carcinoma. J Urol. 188:707–715. 2012.
5	Audenet F, Yates DR, Cancel-Tassin G, Cussenot O and Rouprêt M: Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int. 109:1864–1870. 2012.
6	Bibikova M, Lin Z, Zhou L, et al: High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 16:383–393. 2006.
7	Yoo KH, Park YK, Kim HS, Jung WW and Chang SG: Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Pathol Int. 60:661–666. 2010.
8	Peltomäki P: Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 21:1174–1179. 2003.
9	Marsischky GT, Filosi N, Kane MF and Kolodner R: Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev. 10:407–420. 1996.
10	Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM and Zincke H: Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 173:1889–1892. 2005.
11	Won KY, Kim HS, Sung JY, et al: Tumoral FOXP3 has potential oncogenic function in conjunction with the p53 tumor suppressor protein and infiltrated Tregs in human breast carcinomas. Pathol Res Pract. 209:767–773. 2013.
12	Kouso H, Yoshino I, Miura N, et al: Expression of mismatch repair proteins, hMLH1/hMSH2, in non-small cell lung cancer tissues and its clinical significance. J Surg Oncol. 98:377–383. 2008.
13	Uehara H, Miyamoto M, Kato K, et al: Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma. J Surg Oncol. 92:109–115. 2005.
14	Olasz J, Mándoky L, Géczi L, Bodrogi I, Csuka O and Bak M: Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors. Anticancer Res. 25:4319–4324. 2005.
15	Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. 2003.
16	Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996.
17	Walsh CP, Chaillet JR and Bestor TH: Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet. 20:116–117. 1998.
18	Cui H, Cruz-Correa M, Giardiello FM, et al: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 299:1753–1755. 2003.
19	Xu GL, Bestor TH, Bourc’his D, et al: Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature. 402:187–191. 1999.
20	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.
21	Martin-Subero JI, Ammerpohl O, Bibikova M, et al: A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One. 4:e69862009.
22	Vlaykova T, Mitkova A, Stancheva G, et al: Microsatellite instability and promoter hypermethylation of MLH1 and MSH2 in patients with sporadic colorectal cancer. J BUON. 16:265–273. 2011.
23	Lynch HT and de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 348:919–932. 2003.
24	Nagasaka T, Rhees J, Kloor M, et al: Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res. 70:3098–3108. 2010.
25	Ling ZQ, Zhao Q, Zhou SL and Mao WM: MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 38:326–332. 2012.
26	Skeldon SC, Semotiuk K, Aronson M, et al: Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 63:379–385. 2013.
27	Stoehr C, Burger M, Stoehr R, et al: Mismatch repair proteins hMLH1 and hMSH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma. Pathobiology. 79:162–168. 2012.
28	Chen HC, Bhattacharyya N, Wang L, et al: Defective DNA repair genes in a primary culture of human renal cell carcinoma. J Cancer Res Clin Oncol. 126:185–190. 2000.
29	Leach FS, Koh M, Sharma K, et al: Mismatch repair gene mutations in renal cell carcinoma. Cancer Biol Ther. 1:530–536. 2002.